CN103919766A - Pharmaceutical composition for lowering urine protein and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for lowering urine protein and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN103919766A CN103919766A CN201410183806.9A CN201410183806A CN103919766A CN 103919766 A CN103919766 A CN 103919766A CN 201410183806 A CN201410183806 A CN 201410183806A CN 103919766 A CN103919766 A CN 103919766A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- urine protein
- isorientin
- application
- orientin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for lowering urine protein and an application of the pharmaceutical composition. The composition is prepared from active ingredients and auxiliary materials, wherein the active ingredients include orientin and/or isoorientin. The pharmaceutical composition disclosed by the invention has the effect of lowering urine protein, and especially can be used for treating a nephrotic patient with minimal lesion.
Description
Technical field
The invention belongs to medical technical field, particularly, relate in particular to a kind of pharmaceutical composition and application thereof that reduces urine protein.
Background technology
Albuminuria changes directly related with Pathological, it is the clinical manifestation of Pathological degeneration, lasting albuminuria reveals Toxicity of Kidney by different mechanism table, acceleration nephropathy progress, not only be accompanied by the damage of glomerule and the forfeiture of the normal permeability of glomerule, also cause renal tubular cell inflammation and become fiber-reactive to cause to ask matter damage and fibrosis.To the final purpose of Kidney Disease, be renal function protecting, suppress the sexual development that carries out of kidney disease.Therefore, the medicine that reduces urine protein can slow down the process of kidney disease, suppresses the structure pathological changes of kidney, thus the clinical manifestation that alleviates nephrotic syndrome.
Orientin (3 ', 4 ', 5,7-tetrahydroxy-8-glucopyranosyl flavone) (orientin) and isorientin (3 ', 4 ', 5,7-tetrahydroxy-6-glucopyranosyl flavone) (isoorientin) be Flavonoid substances, isomers, is extensively present in the food such as Herba Sonchi Oleracei, Semen Fagopyri Esculenti, Fructus Crataegi and bamboo sprout each other.It is reported, orientin and isorientin have the effect of removing DPPH free radical and antiinflammatory, and also have certain active anticancer.CN102743375A discloses purposes and the pharmaceutical composition thereof of isorientin, and isorientin has the effect of obvious inflammation-inhibiting, can form a kind of novel potential anti-inflammatory medicaments and be applied.CN102285976A discloses a kind of method of extracting isorientin from Folium Bambosae flavone, and the method comprises the steps: that (1) is by Folium Bambosae flavone anhydrous alcohol solution, filters, and obtains isorientin crude extract; (2) by hybrid resin post on isorientin crude extract, and carry out eluting separation and purification recrystallization; Prepared isorientin is natural extract, has antioxidation, resists myocardial ischemia, and anoxia effect, can be for medicine, food, health product.
By retrieval domestic and foreign literature, still do not find that isorientin has the bioactive bibliographical information that reduces urine protein at present.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition and application thereof that reduces urine protein.
The object of the present invention is achieved like this:
Reduce a pharmaceutical composition for urine protein, by active component and adjuvant, be prepared from, described active component comprises orientin and/or isorientin.
Preferably, reduce as mentioned above the pharmaceutical composition of urine protein, wherein said active component is comprised of orientin or isorientin.
Further preferably, reduce as mentioned above the pharmaceutical composition of urine protein, wherein said pharmaceutical composition is oral formulations, and described oral formulations comprises tablet, capsule, granule.
The present invention proves by rats with adriamycin nephropathy experimental study, to rat model, gavage isorientin after 3 weeks, rat urine albumen is compared model control group and is obviously reduced, and this shows that stomach isorientin has the effect that reduces adriamycin-induced nephropathy in rats urine protein, can be used for nephrotic's treatment.Therefore, the present invention also provides a kind of pharmaceutical applications, that is: orientin or the isorientin application in the medicine of preparation reduction nephrotic urine protein.Described nephrotic is MCN (MCD) patient.
Compared with prior art, the pharmaceutical composition the present invention relates to has the effect that reduces urine protein, this effect may be owing to its stable podocytic process cellularity, form, reducing podocytic process merges, thereby stablize glomerular filtration barrier, alleviate albuminuria, can be used for nephrotic's treatment, especially can be used for MCN patient's treatment.
The specific embodiment
Adriamycin-induced nephropathy in rats is by amycin and metabolite coup injury podocytic process cell thereof or makes podocytic process cellular metabolism disorderly, cause anionic sites in the morphological change of podocyte and basement membrane to change, thereby make molecule barrier and the electrostatic barrier of glomerular filtration membrane impaired, cause the generation of urine protein.This model is similar to mankind's minute lesion (MCD), is domestic and international generally acknowledged minute lesion model.Test example below by pharmaceutical intervention animal model further illustrates the biological activity that isorientin has reduction urine protein.
40 of healthy male SD rats, body constitution 200～220g, is divided into Normal group (10), model control group (15), treatment group (15) at random; Except Normal group, all the other the two groups of equal tail vein injection amycin of rat 4mg/kg (concentration of amycin medicinal liquid is 2mg/mL), with conventional tail vein injection amycin 3.5 mg/kg again that raise after 6 days of standard feed, freely ingest and drink water; Rats in normal control group adopts tail vein injection equal solvent physiologic saline for substitute.After modeling finishes, Normal group and model control group rat adopt 9ml/kg purified water gavage, every day 1 time, gavage 3 weeks; Treatment group rat oral gavage isorientin 100mg/kg, every day 1 time, gavage 3 weeks.
Each group is all collected 24h urine with metabolic cage in after 1d, injection for the first time the 3rd, 7,14,21 and 28 days before injection amycin, with measuring cup, surveys urine amount, shakes up and gets 3mL, and the centrifugal 5min of 3000r/min, removes sediment ,-20 ℃ of Refrigerator stores, urine protein quantitation to be measured.
According to the result of the test of table 1, can find out, compare with Normal group, nephropathy model matched group 0 d, 3 d urine protein without increasing (
p> 0.05), since the 7th day, increase (
p< 0.01), extend and increase gradually in time, within the 21st, 28 days, reach peak; Treatment group urine protein evolution process is similar to nephropathy group, also within the 7th day, start to increase considerably (
p< 0.05 or
p< 0.01), 21d, 28d reach peak, but compare with waiting natural law model control group, urine protein obviously reduce (
p< 0.01).This is indicating that stomach isorientin has the effect that reduces adriamycin-induced nephropathy in rats urine protein.
Table 1 is respectively organized urine protein comparison (g/24h)
With the comparison of equal natural law blank group,
★ p< 0.05;
★ ★ p< 0.01; With the comparison of equal natural law model control group,
▼ p< 0.05,
▼ ▼ p< 0.01.
Claims (5)
1. a pharmaceutical composition that reduces urine protein, is characterized in that: by active component and adjuvant, be prepared from, described active component comprises orientin and/or isorientin.
2. reduce according to claim 1 the pharmaceutical composition of urine protein, it is characterized in that: described active component is comprised of orientin or isorientin.
3. according to the pharmaceutical composition that reduces urine protein described in claim 1 or 2, it is characterized in that: described pharmaceutical composition is oral formulations, and described oral formulations comprises tablet, capsule, granule.
4. orientin or the isorientin application in the medicine of preparation reduction nephrotic urine protein.
5. application according to claim 4, is characterized in that: described nephrotic is MCN patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410183806.9A CN103919766A (en) | 2014-05-04 | 2014-05-04 | Pharmaceutical composition for lowering urine protein and application of pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410183806.9A CN103919766A (en) | 2014-05-04 | 2014-05-04 | Pharmaceutical composition for lowering urine protein and application of pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103919766A true CN103919766A (en) | 2014-07-16 |
Family
ID=51138315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410183806.9A Pending CN103919766A (en) | 2014-05-04 | 2014-05-04 | Pharmaceutical composition for lowering urine protein and application of pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919766A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105983075A (en) * | 2015-02-06 | 2016-10-05 | 云南云百草实验室有限公司 | Traditional Chinese medicinal composition for reducing urinary protein content in patient with chronic renal disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100824635B1 (en) * | 2006-09-13 | 2008-04-24 | 동부일렉트로닉스 주식회사 | Method for Manufacturing Inductor by Using System In Package |
-
2014
- 2014-05-04 CN CN201410183806.9A patent/CN103919766A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100824635B1 (en) * | 2006-09-13 | 2008-04-24 | 동부일렉트로닉스 주식회사 | Method for Manufacturing Inductor by Using System In Package |
Non-Patent Citations (4)
| Title |
|---|
| PAGADALA NATARAJ SEKHAR ET AL: "Experimental validation and docking studies of flavone derivatives on aldose reductase involved in diabetic retinopathy, neuropathy,and nephropathy", 《MEDICINAL CHEMISTRY RESEARCH》, no. 20, 16 September 2010 (2010-09-16), pages 930 - 945, XP 019932229, DOI: doi:10.1007/s00044-010-9412-4 * |
| 原慧等: "一氧化氮和一氧化氮合酶与肾脏的关系研究", 《现代医药卫生》 * |
| 李洪玉等: "竹叶抑制NO合酶活性成分研究", 《浙江中医杂志》 * |
| 齐淑芳等: "山楂叶总黄酮对STZ- DN大鼠肾组织TGF-β1，BMP-7表达的影响", 《中成药》, vol. 32, no. 8, August 2010 (2010-08-01), pages 1414 - 1416 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105983075A (en) * | 2015-02-06 | 2016-10-05 | 云南云百草实验室有限公司 | Traditional Chinese medicinal composition for reducing urinary protein content in patient with chronic renal disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181317B (en) | Purslane extract as well as preparation method and application thereof | |
| CN100453094C (en) | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN102058631B (en) | Seabuckthorn leaf extract preparation and preparation method thereof | |
| CN103169788B (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| WO2011035734A1 (en) | Relinqing extract, preparative method and use thereof | |
| CN102526219A (en) | Extract for Relinqing Granule, as well as preparation method and application of same | |
| CN102805767A (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN107412254A (en) | The application of anoectochilus roxburghii polyose extract | |
| CN104971088A (en) | Tibetan artemisia capillaris extract and preparation method, drug composition and application thereof | |
| CN1985917B (en) | Medicine composition for reducing blood sugar, reducing blood fat and controlling diabetes complication | |
| CN103181930B (en) | Fructus Schisandrae Chinensis effective part of bee pollen form and the application in prevention hepar damnification thereof | |
| CN101638404B (en) | High-purity salvianolic acid B and preparation method and application thereof | |
| CN103919766A (en) | Pharmaceutical composition for lowering urine protein and application of pharmaceutical composition | |
| CN101612184B (en) | Multiradiate fleabane extract, composition containing same, preparation method and application thereof | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN102302545A (en) | Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application | |
| CN105963330A (en) | Miracle fruit preparation and application thereof | |
| KR101738206B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| CN103285082B (en) | Medicament composition for treating gynecological inflammation | |
| CN101804128B (en) | Medicine composition, and use thereof in preparing medicine for curing inflammatory enteropathy | |
| CN102861278B (en) | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof | |
| CN104116753A (en) | Application of aucubin to preparation of medicines for treating idiopathic pulmonary fibrosis | |
| JP2013545767A (en) | Pharmaceutical composition for prevention or treatment of inflammatory diseases comprising a mixture of chondokuto extract and peony skin extract as active ingredients, and method for producing the composition | |
| JP2011184310A (en) | Antiallergic composition derived from fig and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Pan Yaogong Inventor before: Liu Xuejian |
|
| CB03 | Change of inventor or designer information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |
|
| RJ01 | Rejection of invention patent application after publication |